Fewer than a tenth of patients who could benefit from GLP-1 drugs such as Wegovy have access to them, states the World Health Organization as it issues its inaugural recommendations on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging more widespread and fairer availability to GLP-1 medication.
Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The new guidance affirms that excess weight is a long-term condition that can be treated with thorough and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key obstacles to broad access to the treatments that can assist patients in reducing substantial weight, explains the body.
Weight-Loss Drug Scarcity
Despite the present most favorable scenario, the manufacturing of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, according to the WHO.
The guideline calls on countries and companies to widen availability, via strategies such as licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is due to expire in several nations in 2026.
How Obesity Injections Function
The injections replicate a natural hormone to slow digestion, reduce hunger and boost feelings of fullness so people reduce food intake.
Individuals typically begin shedding pounds in the initial weeks of starting on the regular doses.
Research suggests people may regain a significant portion after a year of stopping the drug, when their typical appetite return.
To be above a healthy weight elevates your risk for experiencing medical conditions, such as diabetes, heart disease, stroke, and specific cancers.
Excess weight affects individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, per the health agency.
